185 related articles for article (PubMed ID: 38533694)
1. The engineered exosomes targeting ferroptosis: A novel approach to reverse immune checkpoint inhibitors resistance.
Chen A; Zhang W; Jiang C; Jiang Z; Tang D
Int J Cancer; 2024 Jul; 155(1):7-18. PubMed ID: 38533694
[TBL] [Abstract][Full Text] [Related]
2. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity.
Tang R; Xu J; Zhang B; Liu J; Liang C; Hua J; Meng Q; Yu X; Shi S
J Hematol Oncol; 2020 Aug; 13(1):110. PubMed ID: 32778143
[TBL] [Abstract][Full Text] [Related]
3. Recent progress on targeting ferroptosis for cancer therapy.
Xu G; Wang H; Li X; Huang R; Luo L
Biochem Pharmacol; 2021 Aug; 190():114584. PubMed ID: 33915157
[TBL] [Abstract][Full Text] [Related]
4. Ferroptosis, pyroptosis and necroptosis in hepatocellular carcinoma immunotherapy: Mechanisms and immunologic landscape (Review).
Liu RJ; Yu XD; Yan SS; Guo ZW; Zao XB; Zhang YS
Int J Oncol; 2024 Jun; 64(6):. PubMed ID: 38757345
[TBL] [Abstract][Full Text] [Related]
5. Directly targeting glutathione peroxidase 4 may be more effective than disrupting glutathione on ferroptosis-based cancer therapy.
Wei Y; Lv H; Shaikh AB; Han W; Hou H; Zhang Z; Wang S; Shang P
Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129539. PubMed ID: 31958545
[TBL] [Abstract][Full Text] [Related]
6. Targeted Ferroptosis-Immunotherapy Synergy: Enhanced Antiglioma Efficacy with Hybrid Nanovesicles Comprising NK Cell-Derived Exosomes and RSL3-Loaded Liposomes.
Hao W; Sun N; Fan Y; Chen M; Liu Q; Yang M; Yang Y; Gao C
ACS Appl Mater Interfaces; 2024 Jun; 16(22):28193-28208. PubMed ID: 38776411
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.
Bagchi S; Yuan R; Engleman EG
Annu Rev Pathol; 2021 Jan; 16():223-249. PubMed ID: 33197221
[TBL] [Abstract][Full Text] [Related]
8. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer.
Kobayashi Y; Lim SO; Yamaguchi H
Semin Cancer Biol; 2020 Oct; 65():51-64. PubMed ID: 31874279
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.
Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B
Front Immunol; 2020; 11():1956. PubMed ID: 32983126
[TBL] [Abstract][Full Text] [Related]
11. CD8
Wang W; Green M; Choi JE; Gijón M; Kennedy PD; Johnson JK; Liao P; Lang X; Kryczek I; Sell A; Xia H; Zhou J; Li G; Li J; Li W; Wei S; Vatan L; Zhang H; Szeliga W; Gu W; Liu R; Lawrence TS; Lamb C; Tanno Y; Cieslik M; Stone E; Georgiou G; Chan TA; Chinnaiyan A; Zou W
Nature; 2019 May; 569(7755):270-274. PubMed ID: 31043744
[TBL] [Abstract][Full Text] [Related]
12. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
Naimi A; Mohammed RN; Raji A; Chupradit S; Yumashev AV; Suksatan W; Shalaby MN; Thangavelu L; Kamrava S; Shomali N; Sohrabi AD; Adili A; Noroozi-Aghideh A; Razeghian E
Cell Commun Signal; 2022 Apr; 20(1):44. PubMed ID: 35392976
[TBL] [Abstract][Full Text] [Related]
13. A nanounit strategy reverses immune suppression of exosomal PD-L1 and is associated with enhanced ferroptosis.
Wang G; Xie L; Li B; Sang W; Yan J; Li J; Tian H; Li W; Zhang Z; Tian Y; Dai Y
Nat Commun; 2021 Sep; 12(1):5733. PubMed ID: 34593794
[TBL] [Abstract][Full Text] [Related]
14. Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway.
Zheng X; Luo Y; Xiong Y; Liu X; Zeng C; Lu X; Wang X; Cheng Y; Wang S; Lan H; Wang K; Weng Z; Bi W; Gan X; Jia X; Wang L; Wang Y
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056895
[TBL] [Abstract][Full Text] [Related]
15. The crosstalk between classic cell signaling pathways, non-coding RNAs and ferroptosis in drug resistance of tumors.
Yang L; Chen L; Chen T; Gao X; Xiong Y
Cell Signal; 2023 Feb; 102():110538. PubMed ID: 36436800
[TBL] [Abstract][Full Text] [Related]
16. Adipocyte-Derived Exosomal MTTP Suppresses Ferroptosis and Promotes Chemoresistance in Colorectal Cancer.
Zhang Q; Deng T; Zhang H; Zuo D; Zhu Q; Bai M; Liu R; Ning T; Zhang L; Yu Z; Zhang H; Ba Y
Adv Sci (Weinh); 2022 Oct; 9(28):e2203357. PubMed ID: 35978266
[TBL] [Abstract][Full Text] [Related]
17. The Relationship between Ferroptosis and Tumors: A Novel Landscape for Therapeutic Approach.
Xia X; Fan X; Zhao M; Zhu P
Curr Gene Ther; 2019; 19(2):117-124. PubMed ID: 31264548
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of thioredoxin reductase 1 causes ferroptosis while potentiating anti-PD-1 efficacy in head and neck cancer.
Hsieh MS; Ling HH; Setiawan SA; Hardianti MS; Fong IH; Yeh CT; Chen JH
Chem Biol Interact; 2024 May; 395():111004. PubMed ID: 38636790
[TBL] [Abstract][Full Text] [Related]
19. Extracellular Vesicles in Oncology: from Immune Suppression to Immunotherapy.
Srivastava A; Rathore S; Munshi A; Ramesh R
AAPS J; 2021 Feb; 23(2):30. PubMed ID: 33586060
[TBL] [Abstract][Full Text] [Related]
20. Role of ferroptosis in the pathogenesis and as a therapeutic target of inflammatory bowel disease (Review).
Ocansey DKW; Yuan J; Wei Z; Mao F; Zhang Z
Int J Mol Med; 2023 Jun; 51(6):. PubMed ID: 37203397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
